Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Endothelial Dysfunction in Rheumatoid Arthritis
NCT02908490Phase 2Terminated
- Start
- Apr 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Initial Sildenafil with Initial Placebo (2 arms). Primary endpoint: Brachial Artery Flow Mediated Dilation at 3 months. Started Apr 2017; status: terminated.
02
Drugs
sildenafil
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02908490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908490.